日报更新时间：07-02 06:53
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：方舟生物医药
英文名称：ARCA biopharma
行业：医疗
简介：方舟生物医药公司是一家生物制药公司,该公司主要致力于心血管疾病的基因疗法
电话：1-720-9402200
ARCA biopharma是一家生物制药公司，致力于开发针对心血管疾病的基因靶向疗法。方舟生物公司的主要候选产品是Gencaro，一种药理独特的β受体阻滞剂和轻度血管扩张剂，目前正在临床试验中用于治疗心脏衰竭和左心室功能不全。此外，方舟生物还参与制定AB171的临床前计划，AB171是一种新的化学药剂，用于治疗各种心血管适应症，如外周动脉疾病和慢性心力衰竭。方舟生物公司与美敦力公司(Medtronic, Inc.)签署了一项合作协议，以支持GENETIC-AF 2B期临床试验; 和美国实验室公司（Laboratory Corporation of America）合作，提供配套诊断测试和服务，以支持GENETIC-AF试验。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2018-04-02 | Keuer (Thomas A) | Chief Operating Officer | Sell | 482 | 0.50 |
| 2018-04-01 | Selby (Brian L) | Officer | Sell | 1114 | 0.50 |
| 2018-02-27 | Keuer (Thomas A) | Chief Operating Officer | Sell | 410 | 0.72 |
| 2018-02-26 | VENROCK HEALTHCARE CAPITAL PARTN | Beneficial Owner of More than 10% Class | Sell | 41331 | 0.53 |
| 2018-02-26 | Selby (Brian L) | Officer | Sell | 161 | 0.53 |
| 2018-02-25 | Barris (Peter J) | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | VENROCK HEALTHCARE CAPITAL PARTN | Beneficial Owner of More than 10% Class | Sell | 1500000 | 0.55 |
| 2018-02-25 | Sonsini Peter W | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Sakoda (Jon M) | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Mott (David M) | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Makower (Joshua) | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Growth Equity Opportunities IV, | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Florence (Anthony A JR) | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Baskett (Forest) | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 2018-02-25 | Viswanathan Ravi | Beneficial Owner of More than 10% Class | Sell | 1460209 | 0.50 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Mellon Investments Corporation | -- | -- | -68 | -100.00% | 2019-07-31 |
| Tekla Capital Management LLC | 811227 | 3.10% | 811227 | -- | 2019-07-31 |
| Vanguard Group Inc | 5605 | 0.39% | -100 | -1.75% | 2019-07-31 |
| Dimensional Fund Advisors LP | 3100 | 0.21% | 3100 | -- | 2019-07-31 |
| Fidelity Management & Research Company | 2654 | 0.18% | -- | -- | 2019-07-31 |
| Northern Trust Investments Inc | 872 | 0.06% | 872 | -- | 2019-07-31 |
| BlackRock Asset Management Canada Ltd | 192 | 0.01% | -- | -- | 2019-07-31 |
| BlackRock Fund Advisors | 48 | -- | -- | -- | 2019-07-31 |
| State Street Global Advisors | 3 | -- | -- | -- | 2019-07-31 |
| Panagora Asset Management Inc | -- | -- | -83376 | -100.00% | 2019-03-31 |
| Invesco Capital Management LLC | -- | -- | -3003 | -100.00% | 2019-07-31 |
| Royce & Associates, LP | -- | -- | -326147 | -100.00% | 2019-07-31 |
| Northern Trust Investments N A | 14074 | 0.06% | -- | -- | 2018-12-31 |
| Northern Trust Corp | 14074 | 0.06% | -- | -- | 2018-12-31 |
| Aveo Capital Partners, LLC | 93258 | 0.40% | -- | -- | 2018-12-31 |
| Renaissance Technologies Corp | 818533 | 3.49% | 148074 | 22.09% | 2018-12-31 |
| Geode Capital Management, LLC | 97358 | 0.41% | 48679 | 100.00% | 2018-12-31 |
| Morgan Stanley - Brokerage Accounts | 2000 | 0.01% | -5 | -0.25% | 2018-12-31 |
| Morgan Stanley Smith Barney LLC | 2000 | 0.01% | -5 | -0.25% | 2018-12-31 |
| Advisor Group, Inc. | 1001 | -- | 1001 | -- | 2018-12-31 |
| BlackRock Inc | 865 | -- | -- | -- | 2018-12-31 |
| Bank of America Corporation | 576 | -- | -- | -- | 2018-12-31 |
| Ladenburg Thalmann FI Services Inc | 47 | -- | -- | -- | 2018-12-31 |
| UBS Group AG | 20 | -- | -- | -- | 2018-12-31 |
| Northern Oak Capital Management, Inc. | 13 | -- | -- | -- | 2018-12-31 |
| Vanguard | 2128 | 0.01% | -- | -- | 2019-02-28 |
| Virtu Financial LLC | 100130 | 0.72% | 66002 | 193.40% | 2018-09-30 |
| Acadian Asset Management LLC | 136363 | 0.98% | 136363 | -- | 2018-09-30 |
| BNY Mellon Asset Management North America Corporation | 68 | -- | 68 | -- | 2018-12-31 |
| Reichmuth & Co Integrale Vermogensverwaltung AG | 8500 | 0.06% | 5000 | 142.86% | 2018-11-30 |
| Wellington Management Company LLP | 16100 | 0.12% | 8000 | 98.77% | 2018-11-30 |
| Vanguard Investments Australia Ltd | 44395 | 0.32% | -- | -- | 2018-11-30 |
| Apo Asset Management GmbH | 84651 | 0.61% | 12000 | 16.52% | 2018-11-30 |
| Hauck & Aufh | 95000 | 0.68% | 57000 | 150.00% | 2018-11-30 |
| Franklin Advisers, Inc. | 1216840 | 8.74% | -- | -- | 2018-11-30 |
| Susquehanna International Group, LLP | 47636 | 0.34% | 47636 | -- | 2018-06-30 |
| Susquehanna Financial Group, LLLP | 47636 | 0.34% | 47636 | -- | 2018-06-30 |
| Credit Suisse First Boston (CSFB) | 20001 | 0.14% | 1 | 0.01% | 2018-06-30 |
| Deutsche Bank AG | 352041 | 2.53% | 346951 | 6816.33% | 2018-03-31 |
| VHCP Management, LLC | 1541331 | 13.09% | 1541331 | -- | 2017-12-31 |
| RA Capital Management, LLC | 324490 | 2.76% | 92245 | 39.72% | 2017-12-31 |
| Royce & Associates, LLC | 326147 | 2.35% | 1300 | 0.40% | 2018-03-31 |
| TWO SIGMA SECURITIES, LLC | 32337 | 0.23% | 32337 | -- | 2018-03-31 |
| UBS Securities LLC | 5094 | 0.04% | 5094 | -- | 2018-06-30 |
| Guggenheim Funds Investment Advisors LLC | 3431 | 0.02% | -- | -- | 2018-09-14 |
| Sabby Management LLC | 557652 | 4.74% | 557652 | -- | 2017-12-31 |
| Merrill Lynch & Co Inc | 4 | -- | -200 | -98.04% | 2018-06-30 |
| Columbia Management Company | 572 | -- | -- | -- | 2018-06-30 |
| Mellon Capital Management Corporation | 278 | -- | 68 | 32.38% | 2018-06-30 |
| Morgan Stanley & Co Inc | 245 | -- | 245 | -- | 2018-03-31 |
| Ladenburg Thalmann Asset Management Inc | 47 | -- | 47 | -- | 2018-03-31 |
| BARCLAYS CAPITAL Inc | 73 | -- | 73 | -- | 2018-03-31 |
| Millennium Management LLC | 11124 | 0.09% | 11124 | -- | 2018-03-31 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 10452 | 0.09% | -- | -- | 2017-12-31 |
| Royal Bank Of Canada | 24 | -- | -- | -- | 2017-12-31 |
| NEA Management Company, LLC | 1460209 | 12.40% | -- | -- | 2017-12-31 |
| VHCP Management II, LLC | 1078932 | 9.17% | -- | -- | 2017-12-31 |
| Franklin Advisers Inc | 1216840 | 10.52% | -- | -- | 2017-12-31 |
| Oppenheim Asset Mgmt Services S.¨¤ r.l. | 46100 | 0.39% | -- | -- | 2017-09-30 |
| Reichmuth & Co Privatbankiers | 8500 | 0.08% | 5000 | 142.86% | 2018-01-31 |
| Medical Strategy GmbH | 95000 | 0.88% | 57000 | 150.00% | 2018-01-31 |
| Goldman, Sachs & Co. | 16181 | 0.16% | -558 | -3.33% | 2017-06-30 |
| FMG LLC | 1046 | 0.01% | -- | -- | 2016-11-30 |
| BlackRock Advisors LLC | 1046 | 0.01% | -- | -- | 2016-09-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Vanguard US Equity Index Fund | -- | -- | -2000 | -100.00% | 2018-12-31 |
| NT Ext Equity Mkt Fd - DC - NL | 94 | 0.01% | 94 | -- | 2019-06-30 |
| NT Extended Equity Market Idx Fund - NL | 132 | 0.01% | 132 | -- | 2019-06-30 |
| NT US Market Cap Index Fund - Lending | 172 | 0.01% | 172 | -- | 2019-06-30 |
| NT Ext Equity Market Index Fund - L | 466 | 0.03% | 466 | -- | 2019-06-30 |
| Fidelity | 2654 | 0.18% | -- | -- | 2019-06-30 |
| DFA Tax Managed US Small Cap Portfolio | 3100 | 0.21% | 3100 | -- | 2019-06-30 |
| Vanguard Extended Market Index Fund | 5605 | 0.39% | 1900 | 51.28% | 2019-06-30 |
| Tekla Life Sciences Investors | 811227 | 3.10% | 811227 | -- | 2019-03-31 |
| iShares Core Balanced ETF Portfolio | 48 | -- | -- | -- | 2019-05-30 |
| iShares Core S&P US Total Market ETF | 48 | -- | -- | -- | 2019-05-30 |
| iShares Core S&P Total US Stock Mkt ETF | 48 | -- | -- | -- | 2019-07-30 |
| iShares Core Growth ETF Portfolio | 48 | -- | -- | -- | 2019-05-30 |
| iShares Core MSCI AllCntry Wld exCan ETF | 48 | -- | -- | -- | 2019-05-30 |
| NT Quality SCC US Fund - Non-Lending | 4 | -- | 4 | -- | 2019-06-30 |
| NT Quality SCC Global Fund - Non-Lending | 4 | -- | 4 | -- | 2019-06-30 |
| State Street U.S. Extended Market Index | 3 | -- | -- | -- | 2019-06-30 |
| Invesco Wilshire Micro-Cap ETF | -- | -- | -3003 | -100.00% | 2019-02-22 |
| BNYM Mellon NSL Mkt Completion Fd Instl | -- | -- | -68 | -100.00% | 2018-12-31 |
| NT Ext Equity Mkt Idx Fd - DC - NL | 94 | 0.01% | 94 | -- | 2019-06-30 |
| BNYM Mellon NSL Market Completion Fund | -- | -- | -68 | -100.00% | 2018-12-31 |
| BNYM Mellon SL Mkt Completion Fd | -- | -- | -68 | -100.00% | 2018-12-31 |
| Royce Micro-Cap Trust | -- | -- | -326147 | -100.00% | 2018-06-30 |
| BNY Mellon Market Completion Fund | -- | -- | -68 | -100.00% | 2018-12-31 |
| Vanguard Instl Total Stock Market Idx Fd | -- | -- | -32141 | -100.00% | 2018-03-31 |
| Franklin Biotechnology Discovery Fund | -- | -- | -478077 | -100.00% | 2018-03-31 |
| Vanguard Total Stock Market Index Fund | -- | -- | -44395 | -100.00% | 2018-03-31 |
| Vanguard Balanced Index Fund | -- | -- | -22000 | -100.00% | 2018-03-31 |
| apo Medical Opportunities Institutionell | -- | -- | -24500 | -100.00% | 2018-02-28 |
| APO Medical Opportunities | -- | -- | -60151 | -100.00% | 2018-02-28 |
| RIM Global CC Bioscience | -- | -- | -8500 | -100.00% | 2018-02-28 |
| PHARMA/wHEALTH | -- | -- | -16100 | -100.00% | 2018-02-28 |
| FCP MEDICAL BioHealth-Trends | -- | -- | -95000 | -100.00% | 2018-02-28 |
| DFA US Micro Cap Portfolio | 4900 | 0.04% | -- | -- | 2017-09-30 |
| FCP MEDICAL BioHealth | 95000 | 0.68% | 57000 | 150.00% | 2018-01-31 |
| The Vanguard Total Stock Market Index | 2128 | 0.02% | -- | -- | 2017-11-30 |
| Fidelity Spartan | 48679 | 0.35% | -- | -- | 2018-07-31 |
| Wilshire Micro-Cap ETF | 3431 | 0.02% | -- | -- | 2018-09-14 |
| iShares Core S&P Total US Stock Mkt | 865 | 0.01% | -- | -- | 2018-09-12 |
| BNY Mellon EB DL Mkt Completion | 210 | -- | -- | -- | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 38180 | 0.27% | -- | -- | 2018-07-31 |
| SSgA U.S. Total Market Index Fd Class I | 15 | -- | -1 | -6.25% | 2017-12-31 |
| BNY Mellon Market Completion Fund UC1 | 68 | -- | 68 | -- | 2018-03-31 |
| Royce Micro Cap Trust | 326147 | 2.34% | 1300 | 0.40% | 2018-03-31 |
| Franklin Biotechnology Discovery A | 478077 | 4.14% | -- | -- | 2017-12-31 |
| Vanguard Total Stock Mkt Idx | 44395 | 0.32% | -- | -- | 2018-02-28 |
| Vanguard Balanced Index Inv | 22000 | 0.16% | -- | -- | 2018-02-28 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 32141 | 0.23% | -- | -- | 2018-02-28 |
| iShares Micro-Cap | 14204 | 0.15% | -- | -- | 2017-02-07 |
| AXA/Lord Abbett Micro Cap K | 1046 | 0.01% | -- | -- | 2016-11-30 |
| Mellon Capital EB DL Mkt Completion Fund | 266 | -- | -1 | -0.40% | 2015-09-30 |
| The Vanguard - Total Stk Mkt Idx Trust. CF | 2128 | -- | -- | -- | 2015-10-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 7333 | 0.10% | 7333 | -- | 2015-09-30 |
| Vanguard Instl Total Stock Market Index | 19585 | 0.20% | 8000 | 69.00% | 2015-10-31 |
| FCP OP MEDICAL BioHealthTrends | 22000 | 0.20% | 22000 | -- | 2015-09-30 |
| Franklin Biotechnology Discovery | 5171341 | 8.20% | -- | -- | 2015-07-31 |
| Daniel J. Mitchell | Mr. Dan J. Mitchell is Founding Partner at Sequel Venture Partners LLC since 1996. Mr. Mitchell is a Member at Excel Medical Ventures LLC. He has investment experience with privately held emerging growth companies. Prior to co-founding Sequel in 1996, he was formerly with Institutional Venture Capital Fund at the First National Bank of Chicago, investing primarily in technology companies. Mr. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. He currently sits on the board of Cardiovascular Systems Inc., GlobeImmune, Inc., IntelliDx, Inc., Kalypto Medical & Sierra Neuropharmaceuticals, Inc. |
|---|---|
| Thomas A. Keuer | Presently, Thomas A. Keuer is Chief Operating Officer at ARCA biopharma, Inc. Mr. Keuer previously occupied the position of Senior Vice President-Operations at Insmed, Inc., Vice President-Engineering of Baxter International, Inc. Vice President-Operations at Somatogen, Inc. and Vice President-Engineering for Baxter Healthcare Corp. (both are subsidiaries of Baxter International, Inc.) and Executive Vice President-Pharmaceutical Operations at ARCA biopharma, Inc. Thomas A. Keuer received an undergraduate degree from The University of Texas and a graduate degree from Rice University. |
| Anders D. Hove | Dr. Anders D. Hove is Managing Member at VHCP Management LLC. He is on the Board of Directors at ARCA biopharma, Inc., World Heart Corp., QuatRx Pharmaceuticals Co., Adnexus A Bristol-Myers Squibb R&D Co., Impopharma, Inc. and Intuity Medical, Inc. Dr. Hove was previously employed as an Independent Director by Edge Therapeutics, Inc., an Independent Director by Anacor Pharmaceuticals, Inc., Partner by Venrock Associates, an Asset Manager by BB Medtech AG, Chief Executive Officer by Bellevue Asset Management LLC, a Fund Manager by BB Biotech AG, and a Principal by Ciba-Geigy AG. He also served on the board at Alimera Sciences, Inc., Trubion Pharmaceuticals, Inc., Virdante Pharmaceuticals, Inc., AdvanDx, Inc., Mevion Medical Systems, Inc. and PEAK Surgical, Inc. He received his graduate degree from Technical University of Denmark, an MBA from INSEAD and a doctorate degree from the University of Copenhagen. |
| Robert E. Conway | Presently, Robert E. Conway holds the position of Chairman for Wall Family Enterprise, Inc. and Chairman at ARCA biopharma, Inc. He is also on the board of 6 other companies. In his past career he held the position of Chief Executive Officer & Director at Array BioPharma, Inc., Vice President of Corning, Inc. Vice President & General Manager at Corning-Hazleton, Inc. and Vice President of Corning International Corp. (both are subsidiaries of Corning, Inc.), Advisory Committee Member at Genstar Capital Management LLC and Chief Operating Officer & Executive Vice President at Hill Top Research, Inc. Robert E. Conway received an undergraduate degree from Marquette University and an MBA from the University of Cincinnati (Ohio). |
| Jean-Francois B. Formela | Founder of Translate Bio, Inc., Egalet Corp. and Adnexus, Jean-Francois B. Formela presently holds the position of Partner at Atlas Venture, Inc. and Chairman of IFM Therapeutics LLC. He is also on the board of 19 other companies. In his past career Dr. Formela held the position of Chairman of Egalet Corp. and Chairman at Egalet Ltd. (a subsidiary of Egalet Corp.), Senior Director-Medical Marketing at Schering-Plough Corp. and Director at Adnexus. Dr. Formela received a doctorate from Universit�0�1�0�8 Paris-Sud 11 and an MBA from Columbia University. |
| Michael R. Bristow | Michael R. Bristow is an entrepreneur who founded Myogen, Inc., ARCA biopharma, Inc., miRagen Therapeutics, Inc. and ARCA biopharma, Inc. He occupies the position of President, Chief Executive Officer & Director at ARCA biopharma, Inc. Dr. Bristow is also Professor at the University of Colorado Health Sciences Center. He previously held the position of Chairman, Chief Science & Medical Officer at ARCA biopharma, Inc. and Chief Science & Medical Officer at Myogen, Inc. He received a doctorate and an undergraduate degree from the University of Illinois. |
| Derek K. Cole | Currently, Derek K. Cole holds the position of President for Investor Relations Advisory Solutions LLC and Investor Relations Contact at ARCA biopharma, Inc. He is also on the board of Colorado BioScience Association (former Chairman). Mr. Cole previously occupied the position of Director-Investor Relations for Myogen, Inc., Head-Investor Relations & Corporate Communications at Alexza Pharmaceuticals, Inc., Vice President-Investor Relations at Allos Therapeutics, Inc. and Chairman for National Investor Relations Institute. |
| Linda S. Grais | Linda S. Grais founded SGX Pharmaceuticals, Inc. Dr. Grais is on the board of PRA Health Sciences, Inc., Corvus Pharmaceuticals, Inc., ARCA biopharma, Inc. and Zosano Pharma Corp. She previously held the position of Managing Member & Partner at InterWest Partners, LLC, Attorney at Wilson Sonsini Goodrich & Rosati PC, President, Chief Executive Officer & Director at Ocera Therapeutics, Inc., Executive Vice President for SGX Pharmaceuticals, Inc. and Assistant Clinical Professor at The University of California, San Francisco. She received an undergraduate degree from Yale University, a graduate degree from Stanford Law School and a doctorate from Yale School of Medicine. |
| Christopher David Ozeroff | Founder of ARCA biopharma, Inc. and ARCA biopharma, Inc., Christopher David Ozeroff is Secretary, Senior Vice President & General Counsel of ARCA biopharma, Inc. Mr. Ozeroff is also Professor at The University of Colorado. He previously was Partner at Hogan & Hartson LLP and Secretary & Executive VP-Business Development at ARCA biopharma, Inc. He received an undergraduate degree from Stanford University and a graduate degree from The University of Chicago Law School. |
| Raymond L. Woosley | Founder of Critical Path Institute, Raymond L. Woosley is on the board of Critical Path Institute (former President & Chief Executive Officer), ARCA biopharma, Inc., Arizona Center for Education & Research on Therapeutics and Crediblemeds Worldwide, Inc. and Professor-Emeritus at Arizona Health Sciences Center and Professor at the University of Arizona College of Medicine. In his past career Raymond L. Woosley occupied the position of Director-Cardiovascular Sciences Institute at Georgetown University School of Medicine and Member of Vanderbilt University. He received a doctorate from the University of Louisville and a doctorate from the University of Miami. |
| Ulrike Steinhorst | Ms. Ulrike Steinhorst is an Independent Director at Albioma, an Independent Director at ARCA biopharma, Inc., an Independent Non-Executive Director at Valeo SA, a Senior Vice President at European Aeronautic Defence & Space France SAS, a Chairman at Degussa France Groupe SAS and a Chairman at Rexim SA. She is on the Board of Directors at Albioma, ARCA biopharma, Inc., Mersen SA, Valeo SA, Fondation Imagine and Franco-German Chamber of Commerce. Ms. Steinhorst was previously employed as a Head-Strategy & Planning by Airbus Group SAS and a Head-Human Resources & VP-Executive Development by Degussa AG. She also served on the board at IMAGINE SA. She received her undergraduate degree from Ecole Nationale d'Administration, an undergraduate degree from Pantheon-Assas University and an MBA from �0�1‰cole des Hautes �0�1‰tudes Commerciales de Paris. |
| Brian L. Selby | Presently, Brian L. Selby occupies the position of Chief Accounting Officer & Vice President-Finance at ARCA biopharma, Inc. In the past Mr. Selby occupied the position of Controller for Myogen, Inc., Auditor of Deloitte & Touche LLP and Controller at Genomica Corp. He received an undergraduate degree from Colorado State University and a graduate degree from the University of Colorado at Denver. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
方舟生物医药（ABIO）大涨230%，此前该公司宣布启动治疗新冠肺炎相关性凝血病的AB201开发计划。